Corporate News

Result of AGM

09 June 2025

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that at the AGM held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:

 

Resolution

For

Against

01

572,589,782

33,404

02

522,618,153

49,986,337

03

572,211,914

85,763

04

532,209,384

38,679,812

05

533,474,486

38,667,157

06

525,097,507

38,679,812

07

570,603,589

899,739

08

570,264,453

1,959,346

 

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com

Christopher von Jako, Ph.D., Chief Executive Officer 

Charles Osborne, Chief Financial Officer

Via Walbrook PR

 

 


Stifel (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Nick Harland / Brough Ransom / Ben Good


 


Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus / Marcus Ulker


 

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.

Investor Alert

Sign up for Email Alerts